R1	Has_negation Arg1:T3 Arg2:T2	
R2	AND Arg1:T4 Arg2:T3	
R3	Has_qualifier Arg1:T4 Arg2:T1	
*	OR T8 T9 T11 T10
R4	Has_qualifier Arg1:T8 Arg2:T21	
*	OR T8 T12 T13 T14 T16 T17 T18 T19
R5	Has_qualifier Arg1:T14 Arg2:T15	
R6	Has_qualifier Arg1:T19 Arg2:T20	
R7	Has_qualifier Arg1:T23 Arg2:T24	
*	OR T26 T25
R8	Has_qualifier Arg1:T28 Arg2:T29	
R9	Has_index Arg1:T34 Arg2:T35	
R10	Has_temporal Arg1:T33 Arg2:T34	
*	OR T37 T38
R11	AND Arg1:T37 Arg2:T39	
R12	Has_qualifier Arg1:T47 Arg2:T48	
R13	Has_negation Arg1:T47 Arg2:T46	
R14	AND Arg1:T45 Arg2:T47	
*	OR T43 T44 T45
R15	AND Arg1:T49 Arg2:T53	
R16	Has_qualifier Arg1:T53 Arg2:T52	
R17	Has_negation Arg1:T52 Arg2:T51	
R18	Has_temporal Arg1:T53 Arg2:T50	
R19	Has_index Arg1:T55 Arg2:T56	
R20	Has_temporal Arg1:T54 Arg2:T55	
R21	Has_index Arg1:T59 Arg2:T60	
R22	AND Arg1:T57 Arg2:T58	
R23	Has_temporal Arg1:T57 Arg2:T59	
*	OR T54 T57
*	OR T64 T65
R24	Subsumes Arg1:T63 Arg2:T64	
R25	Has_qualifier Arg1:T70 Arg2:T71	
*	OR T70 T69
R26	Subsumes Arg1:T67 Arg2:T70	
R27	Has_negation Arg1:T67 Arg2:T68	
*	OR T74 T75 T76 T77
R28	Subsumes Arg1:T73 Arg2:T74	
*	OR T81 T82
R29	Has_value Arg1:T81 Arg2:T83	
R30	Has_qualifier Arg1:T4 Arg2:T5	
R31	Has_qualifier Arg1:T4 Arg2:T6	
T1	Qualifier 14 23	any other
T2	Negation 61 75	in addition to
T3	Condition 76 105	Obsessive Compulsive Disorder
T4	Condition 39 60	psychiatric diagnosis
T5	Qualifier 24 31	primary
T6	Qualifier 32 38	DSM-IV
T8	Condition 158 173	eating disorder
T9	Condition 175 199	body dysmorphic disorder
T10	Condition 220 235	substance abuse
T11	Condition 209 216;230 235	alcohol abuse
T12	Condition 271 287	bipolar disorder
T13	Condition 316 329	Schizophrenia
T14	Condition 340 359	psychotic disorders
T15	Qualifier 334 339	other
T16	Condition 361 369	Delirium
T17	Condition 371 379	Dementia
T18	Condition 385 393	Amnestic
T19	Condition 404 423	cognitive disorders
T20	Qualifier 398 403	other
T21	Qualifier 151 157	DSM-IV
T23	Condition 471 491	Personality Disorder
T24	Qualifier 453 470	Axis II Cluster A
T25	Condition 507 538	Antisocial Personality Disorder
T26	Condition 493 503;518 538	Borderline Personality Disorder
T27	Procedure 574 599	mental status examination
T28	Observation 619 645	risk of committing suicide
T29	Qualifier 607 618	significant
T30	Non-query-able 647 676	in the investigator's opinion
T31	Competing_trial 679 750	Subjects with a history of more than three adequate trials with an SSRI
T32	Competing_trial 753 806	Subjects who have had an adequate trial of pregabalin
T33	Procedure 837 850	psychotherapy
T34	Temporal 851 896	in the last 4 months prior to the first visit
T35	Reference_point 885 896	first visit
T36	Non-query-able 899 1017	Subjects who, during the course of the study, would be likely to require treatment with prohibited concomitant therapy
T37	Condition 1045 1052	allergy
T38	Condition 1056 1072	hypersensitivity
T39	Drug 1076 1086	pregabalin
T41	Competing_trial 1089 1293	Subjects who have participated in any clinical trial within 30 days prior to entering the study, or in a clinical trial involving a psychotropic medication within the 6 months prior to entering the study.
T42	Non-query-able 1295 1848	Any subject who has been taking benzodiazepines before entering the study who: 1) cannot tolerate being free of benzodiazepines for 4 weeks, or 2) has signs or symptoms of benzodiazepine withdrawal or rebound at the end of those 4 weeks. Should a patient entering the study, who is currently on benzodiazepines develop discontinuation symptoms with discontinuation of their benzodiazepine, we will treat these symptoms with a more gradual benzodiazepine taper. Study will be delayed until the patient is able to tolerate the discontinuation for 4 weeks.
T43	Condition 1874 1890	seizure disorder
T44	Condition 1892 1914	organic brain disorder
T45	Condition 1920 1948	history of seizure disorders
T46	Negation 1950 1956	except
T47	Condition 1961 1977	febrile seizures
T48	Qualifier 1981 1990	childhood
T49	Condition 2008 2025	thyroid pathology
T50	Temporal 2078 2099	at least three months
T51	Negation 2054 2057	not
T52	Qualifier 2063 2073	stabilized
T53	Procedure 2031 2040	treatment
T54	Drug 2114 2131	neuroleptic drugs
T55	Temporal 2132 2170	in the two months prior to study entry
T56	Reference_point 2159 2170	study entry
T57	Procedure 2174 2203	cognitive behavioural therapy
T58	Condition 2216 2219	OCD
T59	Temporal 2220 2252	within four weeks of study entry
T60	Reference_point 2241 2252	study entry
T61	Pregnancy_considerations 2254 2381	Pregnant or lactating females, or if sexually active and of childbearing potential, not using adequate methods of birth control
T62	Non-query-able 2384 2587	Patients with a history or evidence of a medical condition that would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the trial
T63	Drug 2609 2622	psychotropics
T64	Drug 2646 2658	betablockers
T65	Drug 2669 2684	anticonvulsants
T67	Drug 2686 2702	Sleep medication
T68	Negation 2749 2759	acceptable
T69	Drug 2735 2744	zopiclone
T70	Drug 2716 2731	chloral-hydrate
T71	Qualifier 2711 2715	oral
T73	Procedure 2781 2811	herbal psychoactive treatments
T74	Drug 2818 2832	St John's Wort
T75	Drug 2834 2842	Valerian
T76	Drug 2844 2853	Kava Kava
T77	Drug 2855 2867	L-tryptophan
T79	Non-query-able 2870 3032	Patients with any condition or on any therapy that, in the investigator's opinion, or as indicated in the pregabalin product label, may pose a risk to the subject
T80	Non-query-able 3035 3183	Patients who have had a major life event in the past three months, which in the judgement of the investigator is influencing their current condition
T81	Measurement 3234 3244;3253 3261	laboratory findings
T82	Measurement 3249 3261	ECG findings
T83	Value 3213 3233	significant abnormal
T85	Non-query-able 3262 3298	not resolved by further examinations
